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In	 the	 evolution	 of	 radiation	 oncology	 technology,	 im-
proved	 planning	 and	 treatment	 delivery	 advanced	 from	
two-dimensional	radiotherapy	(2DRT)	to	three-dimensional	
conformal	 radiotherapy	 (3DCRT)	 two	 decades	 ago.	 In	 the	
last	 decade,	 intensity-modulated	 radiation	 therapy	 (IMRT)	
emerged	 in	 addition	 to	 daily	 image	 guidance	 and	 four-
dimensional	 (4D)	 image-based	 motion	 management	 (1).	
Chemoradiotherapy,	which	was	actually	established	mainly	
with	a	2DRT	trial-RTOG	9410,	is	the	current	standard	of	care	
in	patients	with	inoperable	stage	IIIA	or	IIIB	non-small	cell	
lung	cancer	 (NSCLC)	when	compared	 to	 sequential	proto-
cols	 (2-7).	 Currently,	 aggressive	 chemoradiotherapy	 is	 the	
standard,	and	 is	well	accepted	 in	highly	selected	septuage-
narians	with	inoperable	stage	IIIB	NSCLC	(8).	Convention-
al	 doses	 (60-63	Gy)	 of	 3DCRT	were	well-thought-out	 not	
enough	to	succeed	for	desired	local	control	to	avoid	dismal	
survival.	 There	 has	 been	 a	 significant	 challenge	 in	 safely	
escalating	 the	 radiation	dose	over	60	Gy,	while	preserving	
the	critical	organ	at	risk	(OAR)	structures	(9-12).	In	the	last	
decade,	 IMRT	has	 been	 the	 leading	 improvement,	 and	has	
been	considered	as	the	key	solution	for	safe	dose	escalation	
and	delivery.	Other	 accompanying	 challenges	 are	 the	 fight	
with	unpredictable	movement	of	the	tumor	during	the	respi-
ratory	phases,	the	need	to	increase	the	accuracy	of	treatment	
delivery	during	each	fraction,	and	the	necessity	to	clarify	the	
heterogeneity	correction	in	treatment	planning	systems.	The	
newest	technology	has	been	improved	upon	in	recent	years	
by	4D	image-based	motion	capturing	and	the	management	of	
treatment	planning,	 the	evolution	of	calculation	algorithms	
in	treatment	planning	systems	that	are	capable	of	better	es-
timating	the	dose	delivery	to	tumors	and	normal	structures,	
and	 image-guided	 radiotherapy.	All	of	 these	 improvements	
increased	the	daily	setup	accuracy.	There	is	a	requirement	for	
radiotherapy	is	evident	 in	NSCLC,	with	than	60%	of	 these	
patients	 requiring	 radiotherapy	during	 treatment,	 and	more	
than	40%	of	patients	who	receive	radiotherapy	receive	it	dur-
ing	the	initial	treatment	(13,	14).	Therefore,	due	to	the	grow-
ing	struggle	with	 lung	cancer,	 the	current	debate,	based	on	
inclusion	of	all	modern	technology,	is	whether	IMRT	has	an	
advantage	over	3DCRT	in	the	outcomes	of	local	control,	sur-
Chemoradiotherapy	 is	 the	current	standard	of	care	 in	patients	with	
advanced	 inoperable	 stage	 IIIA	or	 IIIB	non-small	 cell	 lung	 cancer	
(NSCLC).	 Three-dimensional	 radiotherapy	 (3DCRT)	 has	 been	 a	
trusted	method	for	a	long	time	and	has	well-known	drawbacks,	most	
of	which	could	be	 improved	by	 Intensity	Modulated	Radiotherapy	
(IMRT).	IMRT	is	not	currently	the	standard	treatment	of	locally	ad-
vanced	NSCLC,	but	almost	all	patients	could	benefit	to	a	degree	in	
organ	 at	 risk	 sparing,	 dose	 coverage	 conformality,	 or	 dose	 escala-
tion.	The	most	 critical	 step	 for	 a	 radiation	oncology	department	 is	
to	 strictly	 evaluate	 its	 own	 technical	 and	 physical	 capabilities	 to	
determine	the	ability	of	IMRT	to	deliver	an	optimal	treatment	plan.	
This	includes	calculating	the	internal	tumor	motion	(ideally	4DCT	or	
equivalent	 techniques),	 treatment	planning	software	with	an	up-to-
date	heterogeneity	correction	algorithm,	and	daily	image	guidance.	It	
is	crucial	to	optimise	and	individualise	the	therapeutic	ratio	for	each	
patient	during	the	decision	of	3DCRT	versus	IMRT.	The	current	liter-
ature	rationalises	the	increasing	use	of	IMRT,	including	4D	imaging	
plus	PET/CT,	and	encourages	 the	applicable	knowledge-based	and	
individualised	 dose	 escalation	 using	 advanced	 daily	 image-guided	
radiotherapy.
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vival,	and	acute	and	late	side	effects	(esophagitis	and	pneu-
monitis).	IMRT	is	a	technological	improvement	in	the	deliv-
ery	of	radiotherapy,	which	provides	the	potential	to	increase	
the	target	coverage	while	decreasing	the	doses	to	the	organ	
at	risk	to	well	below	complication	thresholds	(15).	However,	
it	unfortunately	increases	the	cost	of	treatment.
The	 understanding	 of	 the	 tolerance	 of	 normal	 tissues,	 es-
pecially	lung	tissue,	which	is	a	dose	limiting	organ,	has	 im-
proved	in	last	decade	(16).	As	clinicians	respect	dose-volume	
constraints	to	reduce	the	acute	and	late	side	effects	of	radio-
therapy,	there	is	an	ongoing	effort	in	the	quantitative	analysis	
of	radiotherapy	effects	on	normal	tissue	for	updated	dose	vol-
ume	constraints,	as	well	as	generating	atlases	for	decreasing	
inter-observer	variability	(17-19).	Residual	lung	function	after	
treatment	 is	 a	major	quality	of	 life	 issue	 in	 lung	cancer	pa-
tients,	as	there	are	pretreatment	compromises	based	on	pre-ex-
isting	comorbidities	and	the	primary	tumor	(20).	Chemoradio-
therapy	in	locally	advanced	NSCLC	also	significantly	affects	
lung	function	if	the	critical	dose	thresholds	are	not	respected	
and	the	results	for	decreased	lung	function	parameters	deter-
mined	by	objective	pulmonary	function	tests	(PFTs)	(21-23).	
Therefore,	lung	function	preservation	as	a	dose	limiting	factor	
was	one	of	the	major	reasons	for	investigating	lung	IMRT,	in	
order	 to	spare	as	much	parenchymal	 tissue	as	possible	from	
higher	doses.
The	question	 of	whether	we	need	 IMRT	or	 not	 is	 strictly	
tied	to	questions	of	whether	we	need	dose	escalation,	whether	
we	need	to	decrease	toxicity	related	with	chemoradiotherapy,	
whether	we	have	tools	to	manage	tumor	motion,	whether	we	
have	 adequate	 treatment	 planning	 software	 algorithms,	 or	
whether	or	not	we	have	image	guidance	capabilities.
SIGNIFICANCE OF DOSE ESCALATION IN 
LOCALLY ADVANCED NSCLC
The	dismal	 survival	 rate	 following	a	 local	 recurrence	 in	
patients	 who	 completed	 their	 lung	 cancer	 radiotherapy	 is	
unfortunate	(2).	Machtay	et	al.	(9,	10)	reported	on	11	RTOG	
trials	including	1356	locally	advanced	NSCLC	patients	and	
documented	locoregional	failure	rates	of	46%	and	52%,	and	
overall	survival	(OS)	rates	of	38%	and	15%	at	two	and	five	
years,	respectively.	Locoregional	control	was	recognised	to	
be	operative	in	long	term	survival	of	NSCLC	patients	(10).	
In	order	 to	 improve	 the	 local	 regional	control	 rates,	many	
centers	 initiated	dose	escalation	 trials	 in	 stage	 III	NSCLC	
patients	 to	 observe	 the	 feasibility	 and	 safety	 constraints	
of	 concurrent	 chemoradiotherapy	with	higher	 doses.	Most	
concluded	that	74	Gy	was	a	tolerable	dose	in	the	well-con-
trolled	 setups	 of	 3DCRT	 (24-26).	 From	 a	 study	 including	
106	NSCLC	patients	at	 the	University	of	Michigan,	Kong	
et	al.	(27)	reasoned	that	each	1	Gy	increment	improved	the	
five-year	local	control	rate	by	1.25%	as	decreasing	the	death	
risk	by	3%.	This	suggested	that	higher	radiation	doses	were	
associated	with	better	outcomes.	Increasing	the	dose	of	ra-
diation	was	 reported	 to	 compensate	 the	 negative	 effect	 of	
large	tumor	volume	in	medically	inoperable	node-negative	
early	stage	NSCLC	patients	treated	with	radiotherapy	alone	
(28).	 Zhao	 et	 al.	 (28)	 compared	 a	 biologically	 equivalent	
dose	(BED)	of	≤79.2	Gy	(physical	dose	of	66	Gy	in	2-Gy	
daily	fractions)	versus	>79.2	Gy,	and	reported	that	a	gross	
tumor	volume	 (GTV)	of	>51.8	cm3	 (~4	cm)	caused	 short-
er	median	OS	 rates	of	18.2	months	 in	comparison	 to	23.9	
months	with	a	GTV	of	≤51.8	cm3,	despite	no	survival	dif-
ference	based	on	tumor	volume	remained	for	who	received	
a	BED	of	>79.2	Gy.	Moreover,	patients	with	a	GTV	>51.8	
cm3	had	a	chance	of	longer	median	OS	rates	(30.4	months)	
if	they	received	a	BED	of	>79.2	Gy	in	contrast	to	ones	who	
received	a	BED	of	≤79.2	Gy	(18.2	months).	Wang	et	al.	(12)	
emphasised	 in	 their	 retrospective	 review	of	 the	University	
of	Michigan	chemoradiotherapy	data,	 that	 there	was	a	3%	
reduction	in	the	risk	of	death	with	1	Gy	of	dose	escalation	
in	the	range	of	60-66	Gy.	Memorial	Sloan	Kettering	Cancer	
Center	data	published	by	Rengan	et	al.	(11)	reported	a	high-
er	survival	rate	for	patients	receiving	≥64	Gy	than	for	ones	
receiving	<60	Gy.	Radiotherapy	dose	escalation	along	with	
concurrent	chemotherapy	in	patients	with	stage	III	NSCLC	
was	also	indicated	in	the	RTOG	database	by	Machtay	et	al.	
(9,	 10)	 to	 show	 increased	 local	 control	 and	OS	 rates	by	 a	
1-Gy	increase	in	BED.	This	was	associated	with	an	approxi-
mate	relative	improvement	of	4%	in	survival	and	a	relative	
improvement	 of	 3%	 in	 locoregional	 control.	RTOG	94-10	
compared	 3-arms,	 including	 induction	 versus	 concurrent	
chemoradiation	therapy	at	a	standard	dose	of	60-63	Gy	and	
at	 hyperfractionated	 69.6	 Gy	 delivered	 as	 twice-daily	 1.2	
Gy/fraction,	and	 revealed	 that	dose	escalation	with	hyper-
fractionation	 of	 the	 69.6	Gy	 arm	 had	worse	 survival	 than	
the	60	Gy	arm	(3).	Yuan	et	al.	(29)	reported	a	prospectively	
randomised	dose	escalation	trial	in	patients	with	inoperable	
stage	III	NSCLC	who	were	enrolled	on	3DCRT	of	1.8	to	2	
Gy	and	68	to	74	Gy	for	involved-field	irradiation	(IFI)	cov-
ering	the	primary	tumour	and	involved	lymph	nodes,	or	60	
to	64	Gy	covering	the	primary	tumour	and	involved	lymph	
nodes,	and	elective	nodal	irradiation	(ENI).	Yuan	et	al.	(29)	
documented	a	better	outcome	and	local	control,	as	well	as	
lower	radiation	pneumonitis	rates,	in	the	dose	escalated	(68-
74	Gy)	IFI	arm	than	the	60	Gy	ENI	arm.
Almost	all	dose	escalation	trials	in	advanced	NSCLC	were	
performed	using	the	2D	or	3DCRT	technique	without	4D	im-
age-based	motion	capability.	There	was	always	a	question	re-
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garding	whether	IMRT	and	tumor	motion	management	would	
be	more	 sustainable	 using	 dose	 escalation.	The	most	 recent	
RTOG	0617	trial	in	patients	with	stage	III	NSCLC	comparing	
60	Gy	 to	 74	Gy	 3DCRT	 concurrent	with	 chemotherapy	+/-	
cetuximab	in	four	arms	of	a	2x2	design	closed	accrual	in	the	
high-dose	arm	based	on	a	planned	interim	analysis	with	higher	
dose	crossing	a	futility	boundary.	However,	a	specific	cause	
could	not	be	determined	and	the	reported	toxicity	was	not	in	
agreement	with	the	lower	survival	rates	in	the	high	dose	arm	
(30).	As	it	does	not	seem	rational	to	put	aside	all	the	accumu-
lated	data	from	the	trials	(9-12)	and	conclude	that	dose	escala-
tion	is	not	beneficial,	one	can	easily	claim	that	74	Gy	could	be	
too	toxic	when	delivered	by	the	limited	radiation	techniques	
in	 the	 trial	without	 tumor	motion	management	 of	 4D	 treat-
ment	planning,	 image	guidance,	and	intensity-modulated	ra-
diotherapy	(31).
EVOLUTION IN IMRT
Although	RTOG	9410	paved	the	way	for	standardisation	of	
chemoradiotherapy	with	better	locoregional	control	and	high-
er	OS	rates	than	sequential	chemotherapy	followed	by	radio-
therapy	regimens,	adding	concurrent	chemotherapy	increased	
the	 rate	 of	 grade	 3	 or	 higher	 toxicity	 (50%	 versus	 30%)	 in	
comparison	with	 a	 sequential	 approach	 (3,	 5,	 7).	As	 an	 ad-
vancement	over	2DRT,	3D-CRT	has	been	reported	to	decrease	
toxicity	in	addition	to	allowing	a	dose	escalation	from	60	Gy	
to	74	Gy	in	concurrent	chemoradiotherapy	(24-26).	IMRT	is	
considered	an	innovation	that	can	successfully	reduce	normal	
tissue	toxicity	in	locally	advanced	NSCLC	patients	(32-40).
It	 has	 also	 become	 obvious	 that	 IMRT	needs	 to	 be	 con-
sidered	for	high	dose	radiation	to	avoid	overdose	to	normal	
tissues,	which	 triggered	dosimetric	and	clinical	studies.	As	
Marnitz	et	al.	(41)	at	Charite	Campus	University	Hospital	in	
Berlin	reported	an	average	of	a	16%	possible	dose	escalation	
advantage	with	IMRT	in	comparison	to	3DCRT.	Grills	et	al.	
(32)	reported	a	dosimetric	benefit	comparison	performed	in	
William	Beaumont	Hospital	for	IMRT	versus	3DCRT,	espe-
cially	in	node-positive	patients	and	in	those	with	adherence	
to	the	esophagus.	They	reported	IMRT	was	capable	of	deliv-
ering	25-30%	greater	radiotherapy	doses	than	3D-CRT	under	
the	same	OAR	constraints.	Schwarz	et	al.	(37)	at	The	Neth-
erlands	Cancer	 Institute	 also	 called	 attention	 to	 a	 possible	
advantage	of	IMRT	over	3DCRT.	They	saw	an	average	dose	
increase	as	high	as	35%	with	an	evident	benefit	for	large	and	
concave	tumors	(37).	Chapet	et	al.	(38)	in	Lyon	documented	
significant	heart	sparing	with	IMRT.	Christian	et	al.	(39)	at	
the	Institute	of	Royal	Marsden	reported	that	IMRT	reduced	
the	dose	to	the	lungs	and	improve	the	conformity	of	the	plan	
in	dosimetric	comparison	 to	3DCRT.	Researchers	 from	the	
MD	Anderson	Cancer	Center	noted	that	IMRT	dosimetrical-
ly	had	the	potential	to	decrease	lung	and	esophageal	toxic-
ity,	 in	addition	 to	 sparing	 the	heart	 from	higher	doses	 (34,	
35).	Liu	et	al.	(34)	compared	IMRT	plans	with	the	3D-CRT	
plans	for	which	V20	and	mean	lung	dose	were	reduced	for	
all	cases,	with	median	 reductions	of	8%	and	2	Gy,	 respec-
tively.	Murshed	et	al.	 (35)	also	noted	 that	IMRT	decreased	
the	V10	and	V20,	which	corresponded	to	a	reduction	of	>2	
Gy	in	the	mean	total	lung	dose	and	a	10%	probable	reduc-
tion	in	the	risk	of	radiation	pneumonitis.	They	also	reported	
decreased	volumes	of	the	heart	and	esophagus	irradiated	to	
>40-50	Gy.	 IMRT	dosimetrically	sound	more	suitable	 than	
3DCRT	in	advanced-stage	disease	with	large	and	complicat-
ed	gross	tumor	volumes,	as	well	as	in	adherence	to	critical	
structures	(34,	35).
Although	there	is	no	randomised	trial	comparing	IMRT	and	
3DCRT,	there	are	two	reliable	reports	from	the	MD	Anderson	
Cancer	Center	 that	 retrospectively	 compared	 a	 single	 study	
center	 that	 treated	 patients	 in	 years	with	 a	 substantial	 over-
lap	of	patients:	290	patients	(222,	3DCRT	versus	68,	IMRT)	
between	2000-2005	by	Yom	et	al.	(15)	and	409	patients	(318,	
3DCRT	versus	91,	IMRT)	between	1999-2006	by	Liao	et	al	
(42).	The	common	emphasis	in	both	manuscripts	was	the	re-
duction	 in	critical	 threshold	doses	of	OAR	and	clinical	 side	
effects	directly	related	with	the	quality	of	life.	Yom	et	al.	(15)	
noted	the	good	correlation	of	the	percentage	of	total	lung	vol-
ume	 reduction	 in	patients	 receiving	doses	of	 at	 least	 20	Gy	
radiation	(V20;	38%	with	a	range	of	8-78%	in	3DCRT	versus 
35%	with	a	range	of	20-48%	in	IMRT,	p<0.001),	and	the	re-
duction	in	≥	grade	3	treatment-related	pneumonitis	(TRP;	32%	
at	 12	months	 in	 3DCRT	versus	 8%	at	 12	months	 in	 IMRT,	
p=0.002)	in	favor	of	IMRT.	Liao	et	al.	(42)	also	indicated	the	
significant	 reduction	 in	 ≥	 grade	 3	TRP	 rates	 by	 IMRT	 (ap-
proximate	numbers	derived	from	figures,	~25%	at	12	months	
in	 3DCRT	 versus	 ~10%	 at	 12	 months	 in	 IMRT,	 p=0.017).	
Liao	et	al.	(42)	also	documented	the	overall	outcome	of	two	
cohorts	of	3DCRT	with	conventional	CT	versus	 IMRT	with	
4DCT	planning	in	favor	of	IMRT	with	a	significant	(median	
survival,	10.2	months	in	3DCRT	versus	16.8	months	in	IMRT,	
p=0.039)	OS	rate	difference,	which	could	not	be	directly	at-
tributed	to	IMRT.	
Overall,	all	reports	comparing	3DCRT	and	IMRT	revealed	
that	IMRT	has	the	spirits	to	spare	normal	tissues	from	higher	
doses	of	radiotherapy	in	order	to	decrease	the	notable	side	ef-
fect	 rates,	which	 is	 in	 agreement	with	 the	 potential	 of	 dose	
escalation	for	 local	control	goals.	Therefore,	 it	 is	not	 fair	 to	
ask	which	treatment	technique	is	better.	Based	on	the	ability	of	
IMRT	to	deliver	higher	doses	with	concave	or	sharp	dose	fall-
offs	on	critical	structures	with	the	potential	for	organ	preserva-
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tion,	common	sense	would	indicate	that	all	locally	advanced	
NSCLC	 patients	 would	 be	 treated	 with	 IMRT.	 The	 proper	
question	might	be	which	patients	definitely	need	IMRT,	aside	
from	the	patients	who	could	be	satisfactorily	treated	with	both	
techniques.	Bezjak	et	al.	(43)	published	the	Canadian	Guide-
lines	on	lung	IMRT	and	indicated	a	specific	group	of	patients	
who	could	benefit	the	most	from	IMRT:	tumors	in	close	prox-
imity	to	an	OAR	(e.g.	the	spinal	cord),	a	large	volume	of	OAR	
in	jeopardy	based	on	tumor/target	volume	(e.g.	bilateral	nodal	
volume),	 and	 an	 additional	 dose	 escalation	 requirement	 to	
avoid	increased	toxicity	in	normal	tissue.
UTILISATION OF MOTION AWARENESS 
AND MANAGEMENT
Target	motion	in	correlation	with	 the	respiratory	cycle	 is	
a	major	challenge	for	the	ideal	delivery	of	radiotherapy.	The	
conventional	approach	is	to	both	plan	and	deliver	radiothera-
py	during	a	normal	breathing	pattern	without	any	respiratory	
management,	 but	 using	 a	 larger	 estimated	 volume	with	 an	
additional	margin	to	compensate	the	unknown	motion	during	
treatment.	The	lung	tumor	motion	and	methods	to	cope	with	
it	have	long	been	studied	in	order	to	consider	this	change	in	
lung	cancer	 treatment	planning	(44-46).	The	American	As-
sociation	of	Physicists	in	Medicine	(AAPM)	Task	Group	76	
guidelines	summarised	the	adequate	methods	to	account	for	
this	 obscure	motion	 by	 different	methods:	motion	 encom-
passing	 (slow	CT	scanning;	combination	of	 inhale	and	ex-
hale	breath-hold	CT;	and	4Dimensional-CT/respiration-cor-
related	CT);	respiratory	gating	(internal	fiducial	markers	or	
external	markers	to	signal	respiration);	breath	hold	(self-	or	
device-controlled	 with	 or	 without	 respiratory	monitoring);	
abdominal	compression	for	shallow	breathing;	and	real	time	
tracking	(47).	The	most	accepted	and	user	friendly	method	
seems	 to	 be	 4D-CT	 during	 normal	 breathing,	which	 gives	
an	average	internal	target	volume	(ITV)	model	to	cover	and	
compensate	 respiration-related	 tumor	 motion	 (46,	 48-50).	
The	ITV	approach	provides	individualisation	in	prescription	
by	 designing	 patient-	 and	motion-specific	margins	 that	 in-
corporate	the	extent	of	tumor	motion.
Since	the	motion	could	be	managed	with	4DCT	and	ITV	
utilisation,	 dose	 calculation	was	 another	 concern	 in	 IMRT	
due	 to	 the	 fact	 that	 that	motion	 information	and	change	 in	
density	based	on	movement	were	not	included	in	the	calcula-
tion	in	a	conventional	setting.	Additionally,	breathing-related	
FIG. 1. IMRT with a definitive dose of 60 Gy to the PTV in 30 fractions using a 4D-CT-based ITV approach for a NSCLC patient with T4N3M0 disease.
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intra-fraction	organ	motion	was	an	issue.	However,	the	plans	
after	4DCT	simulation	are	generally	reconstructed	on	an	av-
erage	 intensity	projection	dataset	and	dose	calculations	are	
performed	with	treatment	planning	software	including	mod-
ern	dose	algorithms	based	on	heterogeneity	correction,	such	
as	Monte	Carlo,	collapsed-cone,	convolution/superposition,	
anisotropic	analytical	algorithm,	and	Acuros®	XB	(51-55).	
Additionally,	Bortfeld	 et	 al.	 (56)	 showed	 that	 the	 effect	 of	
organ	motion	during	IMRT	does	not	cause	systematic	errors	
in	dose	delivery	and	it	averages	the	dose	distribution	without	
motion	over	the	path	of	the	tumor	motion,	and	this	is	actually	
not	different	from	conventional	beams.	The	vital	component	
in	 planning	 is	 4D-CT	 simulation,	which	 should	 be	 used	 if	
available.	 If	 it	 is	not	available,	other	alternative	options	 to	
produce	 an	 average	 image	 of	 the	 tumor	 at	 all	 respiratory	
phases,	such	as	spiral	CT	or	slow	CT	scanning,	need	to	be	
considered.	 Based	 on	 the	 complex	 extent	 of	 dose	 shaping	
and	conformity	requirement	in	IMRT	than	3DCRT,	it	ought	
to	be	expressed	that	motion	awareness	and	4D	planning	sup-
port	to	identify	the	margins	of	the	runaway	target	are	more	
critical	for	IMRT	than	for	conventional	3D-CRT.	Therefore,	
the	 planned	 IMRT	doses	with	motion	 awareness	 including	
a	 4DCT	dataset	 and	 current	 heterogeneity	 correction	 algo-
rithms	definitely	represent	the	doses	delivered.
FIG. 2. IMRT with a definitive dose of 70 Gy to the PTV in 35 fractions using a 4D-CT-based ITV approach for a NSCLC patient with T2N2M0 disease.
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FIG. 3. a, b. IMRT-based simultaneous integrated boost to 70 Gy (2 Gy/fraction/day) to integrated gross tumor volume while keeping the conventional 
PTV dose of 63 Gy in 35 fractions using a 4D-CT based ITV approach for a NSCLC patient with T3N2M0 disease; axial and sagittal images (a). IMRT-
based simultaneous integrated boost to 70 Gy (2 Gy/fraction/day) to integrated gross tumor volume while keeping the conventional PTV dose of 63 
Gy in 35 fractions using a 4D-CT based ITV approach for a NSCLC patient with T3N2M0 disease; coronal image (b).
a b
IRRADIATION OF LARGE VOLUMES TO LOW 
DOSES WITH IMRT
As	is	well	known,	the	integral	dose	is	not	expected	to	de-
crease	with	IMRT,	and	the	total	dose	is	deposited	to	the	total	
volume	of	treated	area,	but	mainly	in	the	lung	parenchyma,	
while	reducing	OAR	doses	in	the	esophagus	and	spinal	cord.	
Therefore,	the	lower	doses	spread	around	as	lung	V5	or	V10	
increase	in	comparison	to	3DCRT.	In	treatment	plan	evalu-
ation,	 these	 low	 dose	 parameters	 are	 not	 considered	 alone	
as	 critical	while	 there	 are	 universally	 set	 values	 to	 ensure	
among	all	other	lung	criteria.	Jin	et	al.	(57)	studied	MD	An-
derson	Cancer	Center	data	from	576	inoperable	NSCLC	pa-
tients	 to	 determine	 dose-volume	 thresholds	 for	 the	 risk	 of	
treatment-related	pneumonitis	after	definitive	 radiotherapy.	
The	incidence	of	grade	3	or	more	treatment-related	pneumo-
nitis	was	found	to	be	only	2%	if	the	following	dose-volume	
parameters	 could	be	 achieved:	V5	≤60%,	V10	≤42%,	V20	
≤25%,	V25	≤20%,	V35	≤15%,	and	V50	≤10%.	Wang	et	al.	
(58)	noted	a	collinearity	between	V5	and	V20	for	predicting	
the	risk	of	pneumonia,	but	 they	could	not	define	a	specific	
DVH	parameter	for	V5.	Shi	et	al.	(59)	at	Peking	University	
shared	their	analysis	associated	with	severe	acute	radiation	
pneumonitis	in	NSCLC	patients	treated	with	concurrent	che-
motherapy	and	IMRT.	They	reported	that	keeping	V10	below	
50%	(pneumonia	risk:	V10	≤50%;	5.7%	versus	V10	>50%;	
29.2%)	 was	 a	 useful	 indicator	 for	 avoiding	 pneumonitis.	
Since	 the	 significance	 is	 not	 yet	 known	how	hazardous	 of	
irradiating	large	volumes	to	low	doses,	based	on	the	sparse	
data	of	V5	and	V10	doses	regarding	pneumonitis,	many	cen-
ters	try	to	keep	V5	<60-65%	and	V10	<45%	in	chemoradio-
therapy	protocols	(V5	<55%	and	V10	<40%	in	neoadjuvant	
setting	to	surgery),	in	addition	to	achieving	dose	constraints	
of	mean	lung	dose	and	V20.	The	number	of	IMRT	treatment	
fields	 is	 recommended	 to	 be	 limited	 to	 5-7	 to	 reduce	 lung	
low	dose	exposure	(60).
CONCLUSION
3DCRT	has	been	a	trusted	method	for	a	long	time	and	has	
well-known	drawbacks,	most	of	which	could	be	improved	by	
IMRT.	One	cannot	claim	that	IMRT	is	the	current	standard	in	
NSCLC	treatment,	but	almost	all	patients	could	benefit	 to	a	
degree	in	OAR	sparing,	dose	coverage	conformality,	or	dose	
escalation.	 The	 current	 literature	 and	 our	 own	 institutional	
experience	justify	increasing	the	use	of	IMRT,	including	4D	
imaging	plus	PET	CT,	and	encourage	us	to	proceed	with	the	
applicable	knowledge	and	individualised	dose	escalation	us-
ing	advanced	daily	image	guided	radiotherapy	(1,	15,	19,	42).	
Therefore,	off	clinical	protocol,	we	recommend	delivering	60-
70	Gy	(Figures	1-4)	to	the	planning	target	volume	(PTV)	in	
2	Gy/fraction/day,	or	60-63	Gy	to	the	PTV	in	1.8-2	Gy/frac-
tion/day	plus	an	individualised	simultaneous	integrated	boost	
dose	 escalation	 to	 the	 iGTV	 to	 70	Gy	 in	 2-2.2	Gy/fraction/
day	with	concurrent	chemotherapy	in	patients	with	inoperable	
stage	III	NSCLC	(1).	If	the	patient	is	chemoradiotherapy	in-
eligible	with	a	poor	performance	status	and	is	disposed	for	ra-
diotherapy	alone	or	for	palliation,	the	prescription	might	also	
be	individualised	to	deliver	37.5-45	Gy	(Figure	5)	to	a	PTV	
in	2.5-3	Gy/fraction/day	plus	an	individualised	simultaneous	
integrated	boost	dose	escalation	to	the	iGTV	to	45-52.5	Gy	in	
3-3.5	Gy/fraction/day.
The	most	critical	step	in	a	radiation	oncology	department,	
based	on	“Primum	non	nocere”,	is	to	strictly	evaluate	its	tech-
nical	and	physical	capabilities	to	define	the	IMRT	ability	for	
delivering	 an	 optimal	 treatment	 plan	 including	 calculation	
of	 internal	 tumor	motion	 (ideally	 4DCT	or	 equivalent	 tech-
niques),	 treatment	planning	software	with	an	up-to-date	het-
FIG. 4. IMRT-based simultaneous integrated boost to 66 Gy (2.2 Gy/fraction/day) to an integrated gross tumor volume, while keeping the conventional 
PTV dose of 60 Gy (2 Gy/fraction/day) in 30 fractions using a 4D-CT-based ITV approach for an NSCLC patient with T3N3M0 disease.
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erogeneity	correction	algorithm,	and	daily	image	guidance.	It	
is	crucial	to	optimise	and	individualise	therapeutic	ratio	of	ra-
diotherapy	in	our	lung	cancer	patients	with	applicable	cutting-
edge	technologies.
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